<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03539887</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-17-0903</org_study_id>
    <nct_id>NCT03539887</nct_id>
  </id_info>
  <brief_title>Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to evaluate the potential rapid and sustained antisuicidal and
      antidepressant effects of a single intranasal dose of ketamine in inpatients during a mood
      episode in Major Depressive Disorder (MDD) or Bipolar Disorder (BD) with or without comorbid
      recent abuse of alcohol.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Suicidal ideation as assessed by the Scale for Suicide Ideation (SSI)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidal ideation as assessed by the Scale for Suicide Ideation (SSI)</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidal ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidal ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidal behavior as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidal behavior as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depression as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS)</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recent alcohol abuse as assessed by the Alcohol Urge Questionnaire (AUQ)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Suicidal Ideation</condition>
  <condition>Depression</condition>
  <condition>Alcohol Abuse</condition>
  <arm_group>
    <arm_group_label>Intranasal ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal ketamine in subjects with alcohol abuse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in subjects with alcohol abuse</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal ketamine</intervention_name>
    <description>Intranasal ketamine will be prepared as 100mg/ml ketamine in 0.9% saline. An mucosal atomization device will be used to provide 5 intranasal applications of solution (volume 100 μl), separated by 3 minutes, over a total of 15 minutes. Each of five ketamine applications will provide 10 mg of study drug, for a total of 50mg. The dose to be used (0.5-1mg/Kg) is 6 to 18 times lower than the sedation dose (6-9mg/Kg).</description>
    <arm_group_label>Intranasal ketamine</arm_group_label>
    <arm_group_label>Intranasal ketamine in subjects with alcohol abuse</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline alone. An mucosal atomization device will be used to provide 5 intranasal applications of saline (volume 100 μl), separated by 3 minutes, over a total of 15 minutes.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo in subjects with alcohol abuse</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary admission to Harris County Psychiatry Center

          -  Able to provide written informed consent

          -  Current suicidal ideation and depressive symptoms and Diagnostic and Statistical
             Manual of Mental Disorders -IV- Text Revision(DSM-IV-TR) depressive episode (also
             MADRS greater than or equal to 12) and Young Mania Rating Scale (YMRS) score lower
             than 8

          -  DSM-IV-TR criteria for current alcohol abuse (but not intoxicated/withdrawal,
             abstinent from drinking for &gt; 5 days prior to admission).

          -  Lifetime history of suicide attempt (patient)

          -  Not taking any medication in the last 24hs.

          -  SSI score over 4 (first five items) and Columbia scale (C-SSRS) score 4 or 5

        Exclusion Criteria:

          -  Unstable medical condition or medical problem with known central nervous system (CNS)
             effects, e.g. uncontrolled hypertension systolic blood pressure (SBP) ≥170 and/or
             diasotlic blood pressure (DBP) ≥100) or recent history (6 months) of
             alcohol-withdrawal seizures or significant abnormal laboratory tests (liver function
             test (LFT) 3 times higher than normal).

          -  Prior diagnosis of a DSM-IV-TR psychotic spectrum disorder, psychotic symptoms, or
             personality disorder.

          -  Currently under the acute effects of an illicit substance.

          -  Pregnant or nursing women.

          -  Subjects with a history of DSM-IV drug dependency or abuse (except for caffeine or
             nicotine dependence) within the preceding 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo Machado-Vieira, MD, PhD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rodrigo Machado-Vieira, MD, PhD, MSc</last_name>
    <phone>(713) 741-3830</phone>
    <email>Rodrigo.MachadoVieira@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Cristina Ruiz</last_name>
    <phone>713-741-3951</phone>
    <email>Ana.C.Ruiz@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2018</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Rodrigo Machado-Vieira, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Depression</keyword>
  <keyword>Suicidal Ideation</keyword>
  <keyword>Alcohol Abuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Suicidal Ideation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

